[1]赵倩倩,王惠玲,苏衍进△.糖肾一号方改善早期糖尿病肾病微炎症状态临床研究*[J].陕西中医,2020,(4):443-446.
　ZHAO Qianqian,WANG Huiling,SU Yanjin..Clinical study of Tangshen 1st recipe in improving micro-inflammatory state of early diabetic nephropathy[J].,2020,(4):443-446.
点击复制

糖肾一号方改善早期糖尿病肾病微炎症状态临床研究*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年4期
页码:
443-446
栏目:
临床研究
出版日期:
2020-04-05

文章信息/Info

Title:
Clinical study of Tangshen 1st recipe in improving micro-inflammatory state of early diabetic nephropathy
文章编号:
DOI:10.3969/j.issn.10007369.2020.04.011
作者:
赵倩倩1; 王惠玲2; 苏衍进2△
1.陕西中医药大学(咸阳 712046); 2.陕西中医药大学附属医院(咸阳 712046)
Author(s):
ZHAO Qianqian; WANG Huiling; SU Yanjin.
Shaanxi University of Traditional Chinese Medicine(Xianyang 712046)
关键词:
糖肾一号方;  早期糖尿病肾病;  微炎症状态;  血清肿瘤坏死因子-α;  单核细胞趋化蛋白-1;  细胞内细胞黏附分子-1;  高敏C反应蛋白
Keywords:
Tangshen 1st recipe;  Early diabetic nephropathy;  Micro-inflammatory state;  TNF-α;  MCP-1;  ICAM-1;  hs-CRP
分类号:
R587.2
文献标志码:
A
摘要:
目的:观察糖肾一号方对早期糖尿病肾病(DN)微炎症状态的改善情况,评价该方疗效及对血清炎性因子TNF-α、MCP-1、ICAM-1、hs-CRP的影响。方法:选取60例早期DN患者,随机分为对照组和治疗组。对照组予以盐酸贝那普利片治疗,治疗组予以盐酸贝那普利片和糖肾一号方治疗,两组同时予以相应基础治疗,检测治疗前后24 h尿蛋白定量、尿白蛋白排泄率、空腹血糖、糖化血红蛋白、低密度脂蛋白、血清炎性因子TNF-α、MCP-1、ICAM-1、hs-CRP水平,统计疗效。结果:治疗组总有效率为83.33%,显著高于对照组总有效率的70.00%。治疗后患者24 h尿蛋白定量、尿白蛋白排泄率、低密度脂蛋白、血清炎性因子TNF-α、MCP-1、ICAM-1、hs-CRP水平与治疗前相比均明显下降(P<0.01),且治疗组下降水平明显低于对照组(P<0.05)。两组空腹血糖、糖化血红蛋白水平较治疗前均下降(P<0.01),治疗组下降较对照组明显(P<0.01)。结论:糖肾一号方治疗早期糖尿病肾病可能和其改善微炎症状态有关。
Abstract:
Objective:To observe the improvement of micro-inflammatory state of early diabetic nephropathy with Tangshen 1st recipe,evaluate the effect of the prescription and its effects on serum inflammatory factors TNF-α,MCP-1,ICAM-1,hs-CRP.Methods:Sixty patients with early DN were randomly divided into control group and treatment group.The control group was treated with benazepril hydrochloride tablets.The treatment group was treated with benazepril hydrochloride and Tangshen 1st recipe.The two groups were given corresponding basic treatment.The 24 h urine protein quantitation and urinary albumin excretion rate were measured before and after treatment.Fasting blood glucose,glycosylated hemoglobin,low density lipoprotein,serum inflammatory factors TNF-α,MCP-1,ICAM-1,hs-CRP levels,statistical efficacy.Results:The total effective rate of the treatment group was 83.33%,which was significantly higher than the total effective rate of the control group of 70.00%.After treatment,the 24 h urine protein quantitation,urinary albumin excretion rate,low density lipoprotein,serum inflammatory factors TNF-α,MCP-1,ICAM-1,hs-CRP levels were significantly lower than before treatment(P<0.01).and the treatment group decreased.Significantly lower than that the control group(P<0.05).The levels of fasting blood glucose and glycated hemoglobin in the two groups were lower than those before treatment(P<0.01),and the decrease in the treatment group was significantly higher than that in the control group(P<0.01).Conclusion:The treatment of early diabetic nephropathy with Tangshen 1st recipe may be related to its improvement of micro-inflammation.

参考文献/References:

[1] Guariguata L,Whiting DR,Hambleton I,et al.Global estimates of diabetes prevalence for 2013 and projections for 2035[J].Diabetes Research and Clinical Practice,2014,103(2):137-149.
[2] Yuan CM,Nee R,Ceckowski KA,et al.Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center[J].Clinical Kidney Journal,2016,10(2):257-262.
[3] Li Z,Zhang W.Protective effect of berberine on renal fibrosis caused by diabetic nephropathy[J].Molecular Medicine Reports,2017,16(2):1055-1062.
[4] Barutta F,Bruno G,Grimaldi S,et al.Inflammation in diabetic nephropathy:moving toward clinical biomarkers and targets for treatment[J].Endocrine,2015,48(3):730-742.
[5] 张伊祎,赵铁耘.内毒素诱发胰岛素抵抗机制的研究进展[J].华西医学,2017,32(11):1805-1809.
[6] Hansen TK,Forsblom C,Saraheimo M,et al.Association between mannose-binding lectin,high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes[J].Diabetologia,2010,53(7):1517-1524.
[7] 苏衍进,马居里,王郁金,等.糖肾一号胶囊对早期糖尿病肾病血清 MMP-9 及 TIMP-1 水平影响[J].中成药,2011,33(2):365-366.
[8] 苏衍进,王郁金,王 琴,等.糖肾一号胶囊对糖尿病肾病大鼠血清SREBP-1c、SREBP-2c水平及肾组织IRS-1、PI3K、podocin、CD2AP蛋白表达影响[J].中药药理与临床,2017,33(5):140-143.
[9] 仝小林,刘喜明,魏军平,等.糖尿病中医防治指南[J].中国中医药现代远程教育,2011,9(4):148-151.
[10] Mogensen CE.Microalbuminuria,blood pressure and diabetic renal disease:origin and development of ideas.[J].Diabetologia,1999,42(3):263-285.
[11] 吕仁和,张洁荣,高彦彬.消渴病(糖尿病)中医分期辨证与疗效评定标准[J].中国医药学报,1993,8(3):54-56.
[12] 杨霓芝,刘旭生.糖尿病肾病诊断,辨证分型及疗效评定标准(试行方案)[J].上海中医药杂志,2007,41(7):7-8.
[13] Duran-Salgado MB,Rubio-Guerra AF.Diabetic nephropathy and inflammation[J].World Journal of Diabetes,2014,5(3):393.
[14] 林子桐,张 超,沈雪梅.糖尿病肾病发病机制研究进展[J].中国药理学与毒理学杂志,2014,28(5):765-773.
[15] 胡筱娟,李 群,李 婷,等.糖尿病肾病中医证型与瘀血证相关性研究[J].陕西中医,2012,33(11):1487-1488.
[16] 樊瑞芬.黄芪改善肾病综合征患者血液高凝状态的临床观察[J].中国中西医结合肾病杂志,2001,2(11):672-673.
[17] 王海花,李德成,孙 靓.黄芪的药效成分及药理作用研究[J].中国处方药,2018,16(11):22-23.
[18] 李 杨,王 凡,贾 宁.黄芪甲苷治疗糖尿病及其并发症药理作用研究[J].黑龙江医学,2019,43(1):96-97.
[19] 尤良震,林逸轩,方朝晖,等.黄芪甲苷治疗糖尿病及其并发症药理作用研究进展[J].中国中药杂志,2017,42(24):4700-4706.
[20] 林茂堂.六味地黄丸(汤)药理研究及临床应用新进展[J].内蒙古中医药,2017,36(14):135-136.

备注/Memo

备注/Memo:
*国家自然科学基金青年项目(81704066)；陕西省中医药管理局课题(2019-ZZ-JC040、LCMS038、JCPT005)；陕西省咸阳市科技局课题(2014K04-19)
更新日期/Last Update: 2020-04-13